Abstract

The ability of (4,4)-armchair CNT and its three phosphate functionalized forms (CNT-nH2PO4, n=1–3) were evaluated as novel drug delivery systems (DDSs) for the two commercially well-known anti-osteoporosis drugs namely alendronate (AL) and etidronate (ET). For this purpose, the DFT calculations were accomplished at both B3LYP and B3PW91 levels using 6–31g(d) basis set. The binding energy was increased by increasing number of H2PO4 moieties attached on the CNT with the most negative binding energy was measured for the carrier containing three phosphate groups. The dipole moments of all phosphate containing CNTs were much greater (∼2.2–4.4D) than that of pristine CNT (∼0D). The contour maps proved that when the CNT was functionalized by H2PO4 groups, the symmetric distribution of electric charge was vanished with the charge distribution was the highest asymmetric for the CNT-2H2PO4 while it was the lowest asymmetric for CNT-3H2PO4 leading to the greatest dipole moment for the CNT-2H2PO4 (4.177D) while the smallest dipole moment for the CNT-3H2PO4 (1.614D). Among all compounds, those containing the CNT-3H2PO4 exhibited the smallest band gap energy, chemical potential and hardness but the greatest electronegativity and electrophilicity index which were all suitable and effective for the attachment of drugs onto the bone surface (having partial positive charge due to the presence of Ca2+ as CaCO3) and therefore inhibiting the osteoporosis. Consequently, it was established that the drug-CNT-3H2PO4 was the most appropriate drug-carrier compound for both of the AL and ET drugs and it could be used as the most effective drug vehicle. The attachment of AL, ET drugs as well as the AL-CNT-3H2PO4 and ET-CNT-3H2PO4 drug-carrier systems to the bone tissue was modelled by optimization of the structures of these compounds bonded to the hydroxyapatite (HA)-17water (w). It was found that among these four systems, the AL-CNT-3H2PO4 could be suggested as the most suitable DDS for application in the treatment of osteoporosis.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.